Karuna Therapeu logo

Karuna Therapeu

Stock
Stock
Ticker: KRTX
KRTX

Price

Price

CHART BY

Frequently asked questions

Karuna Therapeu's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -11.73. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Karuna Therapeu's stock, with a consensus target price of $330.00. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Karuna Therapeu reported a revenue of $654.00K.
Karuna Therapeu's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$493.08M. EBITDA measures the company's overall financial performance.
Karuna Therapeu has a free cash flow of -$388.74M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Karuna Therapeu employs approximately 339 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.

Financials

EPS (TTM) 
-11.73
Revenue (TTM) 
$654.00K
EBITDA (TTM) 
-$493.08M
Free Cashflow (TTM) 
-$388.74M

Analyst Ratings

The price target is $330.00 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Employees
339
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
KRTX

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation